RenovoRx (RNXT) Projected to Post Earnings on Friday

RenovoRx (NASDAQ:RNXT) is projected to release its Q1 2025 earnings data before the market opens on Friday, May 9th. Analysts expect RenovoRx to post earnings of ($0.10) per share and revenue of $0.23 million for the quarter.

RenovoRx (NASDAQ:RNXT) last announced its quarterly earnings results on Monday, March 31st. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The business had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.17 million. On average, analysts expect RenovoRx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

RenovoRx Trading Up 3.1 %

Shares of NASDAQ:RNXT opened at $0.99 on Friday. RenovoRx has a 12-month low of $0.75 and a 12-month high of $1.69. The company has a market capitalization of $36.19 million, a PE ratio of -1.74 and a beta of 1.12. The business has a 50 day moving average of $0.95 and a two-hundred day moving average of $1.13.

Wall Street Analysts Forecast Growth

RNXT has been the subject of a number of recent analyst reports. Ascendiant Capital Markets lifted their price target on shares of RenovoRx from $9.00 to $11.00 and gave the company a “buy” rating in a research report on Monday. HC Wainwright reiterated a “buy” rating and set a $3.00 price target on shares of RenovoRx in a research report on Friday, April 4th.

RenovoRx Company Profile

RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.